Page updated ·next FDA decision on the calendar·Data as of Nov 5, 2026 9:00 PM ET
Price into the decision (T-120)
Daily close, T-120 (11/27/24) through T+5. Run-up high $216.66 on 3/11/25, low $166.28 on 11/27/24 (T-120 to T-1). FDA decision 5/14/25. Historical price action, not a forecast.
Positioning before the decision
On Apr 30, 2025, 14 days before the decision date, at-the-money options priced a move of ±4.3% through May 16, 2025 (the first listed expiry after the decision; ATM implied volatility 26%). The stock closed -5.6% at the first close across the decision and -1.7% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Every FDA approval letter and released Complete Response Letter we hold, by FDA action date: FDA approval letters.
Questions
Was EMRELIS (Telisotuzumab vedotin (Teliso-V)) approved by the FDA?
Yes. The FDA approved the application for EMRELIS (Telisotuzumab vedotin (Teliso-V)) on May 14, 2025, per the FDA's own record. The primary source is linked on this page.
What was EMRELIS (Telisotuzumab vedotin (Teliso-V)) under FDA review for?
The application covered Nonsquamous non-small cell lung cancer (NSCLC). The FDA approved the application on May 14, 2025.
How did ABBV stock react to the FDA decision?
On the decision day ABBV moved -5.6%. That is the recorded reaction to this specific event. Historical measurement, not a prediction, and not investment advice.